David D Waters

List of Publications by Citations

66 papers	8,057 citations	27 h-index	89 g-index
99 ext. papers	9,821 ext. citations	8.8 avg, IF	5.53 L-index

#	Paper	IF	Citations
66	Effects of torcetrapib in patients at high risk for coronary events. *New England Journal of Medicine*, **2007**, 357, 2109-22	59.2	2323
65	Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). *JAMA - Journal of the American Medical Association*, **2002**, 288, 49-57	27.4	1150
64	Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. *New England Journal of Medicine*, **2019**, 381, 2497-2505	59.2	861
63	HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. *Lancet, The*, **2015**, 385, 351-61	40	409
62	Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. *JAMA - Journal of the American Medical Association*, **2002**, 288, 2432-40	27.4	389
61	Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. *Journal of the American College of Cardiology*, **2014**, 64, 485-94	15.1	372
60	Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. *Journal of the American College of Cardiology*, **2011**, 57, 1535-45	15.1	259
59	Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. *Circulation*, **2009**, 120, 28-34	16.7	253
58	Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses. *Aids*, **2006**, 20, 2275-83	3.5	213
57	Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. *Circulation*, **2002**, 106, 1690-5	16.7	156
56	Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?. *American Journal of Cardiology*, **2004**, 93, 154-8	3	151
55	Body-Weight Fluctuations and Outcomes in Coronary Disease. *New England Journal of Medicine*, **2017**, 376, 1332-1340	59.2	150
54	Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes. *Journal of the American College of Cardiology*, **2013**, 61, 148-52	15.1	130
53	Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial. *Lancet Respiratory Medicine,the*, **2021**, 9, 924-932	35.1	91
52	The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. *European Heart Journal*, **2015**, 36, 1536-46	9.5	88
51	Randomized double-blind comparison of two doses of Hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction. *Circulation*, **1995**, 91, 2132-9	16.7	80
50	Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial. *Circulation*, **2018**, 138, 770-781	16.7	65

49	Inflammation, statin therapy, and risk of stroke after an acute coronary syndrome in the MIRACL study. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2008**, 28, 142-7	9.4	57
48	Safety of high-dose atorvastatin therapy. *American Journal of Cardiology*, **2005**, 96, 69F-75F	3	51
47	HIV infection and coronary heart disease: mechanisms and management. *Nature Reviews Cardiology* , **2019**, 16, 745-759	14.8	44
46	Relation of Variability of Low-Density Lipoprotein Cholesterol and Blood Pressure to Events in Patients With Previous Myocardial Infarction from the IDEAL Trial. *American Journal of Cardiology*, **2017**, 119, 379-387	3	41
45	Prediction of cardiovascular events in statin-treated stable coronary patients of the treating to new targets randomized controlled trial by lipid and non-lipid biomarkers. *PLoS ONE*, **2014**, 9, e114519	3.7	34
44	Impact of female sex on lipid lowering, clinical outcomes, and adverse effects in atorvastatin trials. *American Journal of Cardiology*, **2015**, 115, 447-53	3	33
43	Statin and the risk of renal-related serious adverse events: Analysis from the IDEAL, TNT, CARDS, ASPEN, SPARCL, and other placebo-controlled trials. *American Journal of Cardiology*, **2014**, 113, 2018-20	3	32
42	Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk. *Journal of Clinical Lipidology*, **2018**, 12, 130-136	4.9	27
41	Body Weight Variability and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus. *Circulation: Cardiovascular Quality and Outcomes*, **2018**, 11, e004724	5.8	27
40	Visit-to-visit variability of lipid measurements as predictors of cardiovascular events. *Journal of Clinical Lipidology*, **2018**, 12, 356-366	4.9	26
39	2013 Cholesterol Guidelines Revisited: Percent LDL Cholesterol Reduction or Attained LDL Cholesterol Level or Both for Prognosis?. *American Journal of Medicine*, **2016**, 129, 384-91	2.4	26
38	Cholesterol lowering. Should it continue to be the last thing we do?. *Circulation*, **1999**, 99, 3215-7	16.7	25
37	Effect of change in body weight on incident diabetes mellitus in patients with stable coronary artery disease treated with atorvastatin (from the treating to new targets study). *American Journal of Cardiology*, **2014**, 113, 1593-8	3	22
36	Early statin therapy in acute coronary syndromes: the successful cycle of evidence, guidelines, and implementation. *Journal of the American College of Cardiology*, **2009**, 54, 1434-7	15.1	22
35	Impact of high-dose atorvastatin therapy and clinical risk factors on incident aortic valve stenosis in patients with cardiovascular disease (from TNT, IDEAL, and SPARCL). *American Journal of Cardiology* , **2014**, 113, 1378-82	3	21
34	Myocardial Infarction in the ISCHEMIA Trial: Impact of Different Definitions on Incidence, Prognosis, and Treatment Comparisons. *Circulation*, **2021**, 143, 790-804	16.7	21
33	Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). *European Heart Journal Quality of Care & Clinical Outcomes*, **2021**, 7, 486-495	4.6	18
32	Cardiovascular drugs that increase the risk of new-onset diabetes. *American Heart Journal*, **2014**, 167, 421-8	4.9	18

31	Exploring new indications for statins beyond atherosclerosis: Successes and setbacks. *Journal of Cardiology*, **2010**, 55, 155-62	3	18
30	The Myocardial Ischemia Reduction with Acute Cholesterol Lowering (MIRACL) trial: a new frontier for statins?. *Current Controlled Trials in Cardiovascular Medicine*, **2001**, 2, 111-114		17
29	Lipid Abnormalities in Persons Living With HIV Infection. *Canadian Journal of Cardiology*, **2019**, 35, 249-258	3.8	17
28	An Evidence-Based Guide to Cholesterol-Lowering Guidelines. *Canadian Journal of Cardiology*, **2017**, 33, 343-349	3.8	13
27	Variations in time to benefit among clinical trials of cholesterol-lowering drugs. *Journal of Clinical Lipidology*, **2018**, 12, 857-862	4.9	13
26	Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapib. *American Heart Journal*, **2020**, 222, 157-165	4.9	10
25	Body-Weight Fluctuations and Outcomes in Coronary Disease. *New England Journal of Medicine*, **2017**, 377, 95-6	59.2	10
24	LDL-cholesterol lowering and renal outcomes. *Current Opinion in Lipidology*, **2015**, 26, 195-9	4.4	10
23	Statins and safety: applying the results of randomized trials to clinical practice. *American Journal of Cardiology*, **2003**, 92, 692-5	3	10
22	High plasma FGF21 levels predicts major cardiovascular events in patients treated with atorvastatin (from the Treating to New Targets [TNT] Study). *Metabolism: Clinical and Experimental*, **2019**, 93, 93-99	12.7	10
21	Postscripts from the Post-Coronary Artery Bypass Graft trial: the sustained benefit of more aggressive cholesterol lowering and the enigma of low-dose anticoagulation. *Circulation*, **2000**, 102, 144-6	16.7	9
20	Metabolic Markers to Predict Incident Diabetes Mellitus in Statin-Treated Patients (from the Treating to New Targets and the Stroke Prevention by Aggressive Reduction in Cholesterol Levels Trials). *American Journal of Cardiology*, **2016**, 118, 1275-1281	3	9
19	PCSK9 Inhibition to Reduce Cardiovascular Risk: Tempering Expectations. *Circulation Research*, **2017**, 120, 1537-1539	15.7	8
18	What do the statin trials tell us?. *Clinical Cardiology*, **2001**, 24, III3-7	3.3	6
17	Clinical insights from the Treating to New Targets trial. *Progress in Cardiovascular Diseases*, **2009**, 51, 487-502	8.5	5
16	Low-Density-Lipoprotein Cholesterol Goals for Patients With Coronary Disease. *Circulation*, **2001**, 104, 2635-2637	16.7	5
15	Statin-centric versus low-density lipoprotein-centric approach for atherosclerotic cardiovascular disease prevention: a Singapore perspective. *Singapore Medical Journal*, **2016**, 57, 360-7	1.9	5
14	PCSK9 Inhibition to Lower LDL-Cholesterol and Reduce Cardiovascular Risk: Great Expectations. *Circulation Research*, **2015**, 116, 1643-5	15.7	4

List of Publications

13	Emerging Cardiovascular Disease Biomarkers and Incident Diabetes Mellitus Risk in Statin-Treated Patients With Coronary Artery Disease (from the Treating to New Targets [TNT] Study). *American Journal of Cardiology*, **2016**, 118, 494-8	3	4
12	The past and future of heart institutes: having moved beyond the one-trick pony. *Canadian Journal of Cardiology*, **2014**, 30, S478-82	3.8	3
11	Lipids, inflammation, and chronic kidney disease: a SHARP perspective. *Kidney International*, **2018**, 93, 784-786	9.9	2
10	Cholesterol Lowering Guidelines: From Whence We Came and Where We Are Now. *Canadian Journal of Cardiology*, **2019**, 35, 590-597	3.8	2
9	Pharmacogenomics of the Efficacy and Safety of Colchicine in COLCOT. *Circulation Genomic and Precision Medicine*, **2021**, 14, e003183	5.2	2
8	Relationship of High-Density Lipoprotein Cholesterol With Renal Function in Patients Treated With Atorvastatin. *Journal of the American Heart Association*, **2018**, 7,	6	1
7	RE: Praluent (Alirocumab)-Induced Renal Injury. *Journal of Pharmacy Practice*, **2018**, 31, 138-139	1.3	1
6	Are Cholesterol Treatment Targets a Deterrent to Optimal Lipid-Lowering Therapy?. *JAMA Cardiology*, **2017**, 2, 1392-1393	16.2	1
5	Utility of biomarkers and imaging in the development of drugs for the treatment of coronary atherosclerosis. *Canadian Journal of Cardiology*, **2012**, 28, 687-92	3.8	1
4	Role of Adenylate Cyclase 9 in the Pharmacogenomic Response to Dalcetrapib: Clinical Paradigm and Molecular Mechanisms in Precision Cardiovascular Medicine. *Circulation Genomic and Precision Medicine*, **2021**, 14, e003219	5.2	0
3	Notes From Cardiology Clinic: Brittle Bones and Blue Sclerae. *Canadian Journal of Cardiology*, **2020**, 36, 1009-1010	3.8	
2	TNT Trial **2008**, 1		
1	Erratum to "Notes From Cardiology Clinic: The Patients We Dislike": Can J Cardiol 36 (2020) 157-158. *Canadian Journal of Cardiology*, **2020**, 36, 965	3.8	